Kiora Pharmaceuticals (KPRX) Operating Expenses (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Operating Expenses came in at $2.5 million in Q1 2026, up 7.72% YoY from $2.3 million in Q1 2025, and down 65.66% on a QoQ basis from $7.3 million in Q4 2025.
Kiora Pharmaceuticals (KPRX) Operating Expenses (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 13 years of Operating Expenses data on file, last reported at $2.5 million in Q1 2026.
- Quarterly Operating Expenses rose 7.72% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.0 million (up 17.62% YoY) and the FY2025 annual result came in at $12.8 million, up 11.48% from the prior year.
- Operating Expenses retreated to $2.5 million in Q1 2026, from $7.3 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $7.3 million in Q4 2025 to a low of $794437.0 in Q3 2025.
- A 5-year average of $3.0 million and a median of $2.6 million in 2024 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 185.03% in 2025, down 77.95% in 2025.
- Tracing KPRX's Operating Expenses over 5 years: stood at $2.6 million in 2022, then decreased by 19.6% to $2.1 million in 2023, then gained by 21.05% to $2.6 million in 2024, then soared by 185.03% to $7.3 million in 2025, then sank by 65.66% to $2.5 million in 2026.
- The last three Operating Expenses figures came in at $2.5 million (Q1 2026), $7.3 million (Q4 2025), and $794437.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Kiora Pharmaceuticals | 16.25 Mn | 16.25 Mn | - | 2.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.21 Mn |
| Mar 31, 2026 | 2.51 Mn |
| Dec 31, 2025 | 7.31 Mn |
| Sep 30, 2025 | 794,437.00 |
| Jun 30, 2025 | 2.40 Mn |
| Mar 31, 2025 | 2.33 Mn |
| Dec 31, 2024 | 2.56 Mn |
| Sep 30, 2024 | 3.60 Mn |
| Jun 30, 2024 | 2.56 Mn |
| Mar 31, 2024 | 2.78 Mn |
| Dec 31, 2023 | 2.12 Mn |
| Sep 30, 2023 | 5.92 Mn |
| Jun 30, 2023 | 2.63 Mn |
| Mar 31, 2023 | 1.92 Mn |
| Dec 31, 2022 | 2.63 Mn |
| Sep 30, 2022 | 3.70 Mn |
| Jun 30, 2022 | 2.40 Mn |
| Mar 31, 2022 | 3.57 Mn |
| Dec 31, 2021 | 6.37 Mn |
| Sep 30, 2021 | 3.04 Mn |